Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Geron ( (GERN) ).
On January 12, 2025, Geron Corporation issued 2026 financial guidance, projecting RYTELO net product revenue of $220 million to $240 million and total operating expenses of $230 million to $240 million, signaling anticipated top-line growth alongside a year-over-year reduction in operating spending. Management said the outlook reflects a more focused commercial push for RYTELO, including tighter healthcare professional and patient targeting with expected stronger revenue in the second half of 2026, while a recent strategic restructuring is intended to streamline operations, support its LR-MDS franchise, and preserve balance sheet strength. The company highlighted expanded clinical evidence for RYTELO presented at the 2025 American Society of Hematology meeting, steps to align its cost base with its commercial and development priorities, and an amendment to its term loan facility with Pharmakon Advisors extending the window to draw additional tranches, moves that collectively underpin its drive to entrench RYTELO in LR-MDS, advance late-stage trials and position Geron as a sustainable hematology-focused player for patients and shareholders.
The most recent analyst rating on (GERN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.
Spark’s Take on GERN Stock
According to Spark, TipRanks’ AI Analyst, GERN is a Neutral.
The score is held down primarily by weak financial quality (continued losses and negative operating/free cash flow) despite improving revenue and very strong gross margins. Technicals are neutral-to-mixed and valuation is constrained by a negative P/E. Offsetting factors include a cautiously constructive earnings-call outlook supported by account growth and a strong cash balance, with corporate actions adding flexibility but also highlighting near-term pressure.
To see Spark’s full report on GERN stock, click here.
More about Geron
Geron Corporation is a commercial-stage biopharmaceutical company focused on hematology and blood cancers, built around its first-in-class telomerase inhibitor RYTELO (imetelstat). RYTELO is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) and transfusion-dependent anemia, and Geron is also advancing a pivotal Phase 3 IMpactMF trial of imetelstat in relapsed/refractory myelofibrosis and exploring its use in other hematologic malignancies.
Average Trading Volume: 7,582,966
Technical Sentiment Signal: Sell
Current Market Cap: $874.5M
For an in-depth examination of GERN stock, go to TipRanks’ Overview page.